References

Unresolved reference

External reference

Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial

10.1016/s0140-6736(19)31131-6 · 2019 · External reference

Intensitymodulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial

10.1016/s1470-2045(19)30569-8 · 2019 · External reference

Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer

10.1002/cncr.30101 · 2016 · External reference

Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer

10.1016/j.ijrobp.2010.11.054 · 2012 · External reference

Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer

10.1200/jco.2010.31.4377 · 2011 · External reference

Stereotactic body radiotherapy as treatment for organ confined low- and intermediate-risk prostate carcinoma, a 7-year study

10.3389/fonc.2014.00240 · 2014 · External reference

Prostate-specific antigen 5 years following stereotactic body radiation therapy for low and intermediate-risk prostate cancer: an ablative procedure?

10.3389/fonc.2017.00157 · 2017 · External reference

Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer

10.1001/jamanetworkopen.2018.8006 · 2019 · External reference

NCCN clinical practice guidelines in oncology (NCCN guidelines®): prostate Cancer

2022 · External reference

Unresolved reference

2014 · External reference

Guidelines for primary radiotherapy of patients with prostate cancer

10.1016/j.radonc.2006.05.012 · 2006 · External reference

Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer

10.1186/s13014-015-0351-6 · 2015 · External reference

Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience

10.1186/1748-717x-8-58 · 2013 · External reference

Stereotactic body radiation therapy for localized prostate Cancer: a systematic review and Meta-analysis of over 6,000 patients treated on prospective studies

10.1016/j.ijrobp.2019.03.051 · 2019 · External reference

Quality of life after definitive linear accelerator-based stereotactic radiotherapy for prostate cancer: a longitudinal study

10.1186/s13014-022-02061-y · 2022 · External reference

Hypofractionated radiation therapy for localized prostate Cancer: an ASTRO, ASCO, and AUA evidence-based guideline

10.1200/jco.18.01097 · 2018 · External reference

Dose escalation for prostate stereotactic ablative radiotherapy (SABR): late outcomes from two prospective clinical trials

10.1016/j.radonc.2018.03.005 · 2018 · External reference

Five-year outcomes of a phase 1 dose-escalation study using stereotactic body radiosurgery for patients with low-risk and intermediate-risk prostate cancer

10.1016/j.ijrobp.2018.12.045 · 2019 · External reference

Prostate SBRT: comparison the efficacy and toxicity of two different dose fractionation schedules

10.3389/fonc.2020.00936 · 2020 · External reference

In curative stereotactic body radiation therapy for prostate cancer, there is a high possibility that 45 Gy in five fractions will not be tolerated without a hydrogel spacer

10.3390/cancers16081472 · 2024 · External reference

A multi-institutional phase 2 trial of high-dose ASbR for prostate cancer using rectal spacer

10.1016/j.ijrobp.2021.03.025 · 2021 · External reference

A multi-institutional clinical trial of rectal dose reduction via injected polyethylene-glycol hydrogel during intensity modulated radiation therapy for prostate cancer: analysis of dosimetric outcomes

10.1016/j.ijrobp.2012.12.019 · 2013 · External reference

Hydrogel spacer prospective multicenter randomized controlled pivotal trial: dosimetric and clinical effects of perirectal spacer application in men undergoing prostate image guided intensity modulated radiation therapy

10.1016/j.ijrobp.2015.04.030 · 2015 · External reference

Continued benefit to rectal separation for prostate radiation therapy: final results of a phase III trial

10.1016/j.ijrobp.2016.12.024 · 2017 · External reference

Stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer: toxicity profile and early oncologic outcomes

10.1186/s13014-019-1346-5 · 2019 · External reference

Combining androgen deprivation and radiation therapy in the treatment of localised prostate cancer: summary of level 1 evidence and current gaps in knowledge

2022 · External reference

Interplay between duration of androgen deprivation therapy and external beam radiotherapy with or without a brachytherapy boost for optimal treatment of highrisk prostate cancer: a patient-level data analysis of 3 cohorts

10.1001/jamaoncol.2021.6871 · 2022 · External reference

Enhancing androgen deprivation therapy (ADT) integration in prostate cancer: insights for stereotactic body radiotherapy (SBRT) and brachytherapy modalities

2024 · External reference

Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial

10.1016/s1470-2045(22)00517-4 · 2022 · External reference

Magnetic resonance imaging versus computed tomography guidance for stereotactic body radiotherapy in prostate cancer: 2-year outcomes from the MIRAGE randomized clinical trial

10.1016/j.eururo.2024.10.026 · 2025 · External reference

Systemic and tumor-directed therapy for Oligorecurrent metastatic prostate Cancer (SATURN): primary endpoint results from a phase 2 clinical trial

10.1016/j.eururo.2024.01.021 · 2024 · External reference